Mark E. Boulding
2021
In 2021, Mark E. Boulding earned a total compensation of $4.3M as Executive Vice President and Chief Legal Officer at PTC Therapeutics, a 21% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $298,700 |
|---|---|
| Option Awards | $2,790,550 |
| Salary | $503,938 |
| Stock Awards | $678,198 |
| Other | $21,456 |
| Total | $4,292,842 |
Boulding received $2.8M in option awards, accounting for 65% of the total pay in 2021.
Boulding also received $298.7K in non-equity incentive plan, $503.9K in salary, $678.2K in stock awards and $21.5K in other compensation.
Rankings
In 2021, Mark E. Boulding's compensation ranked 3,096th out of 12,415 executives tracked by ExecPay. In other words, Boulding earned more than 75.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,096 out of 12,415 | 75th |
Division Manufacturing | 1,241 out of 5,505 | 78th |
Major group Chemicals And Allied Products | 500 out of 2,375 | 79th |
Industry group Drugs | 442 out of 2,096 | 79th |
Industry Pharmaceutical Preparations | 302 out of 1,546 | 81st |
Source: SEC filing on April 28, 2022.
Boulding's colleagues
We found four more compensation records of executives who worked with Mark E. Boulding at PTC Therapeutics in 2021.